Post-market Clinical Investigation of the Angio-Seal™ VIP VCD (ANGIO-SEAL CLOSE)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

230 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-09-30

Study Completion Date

2023-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The present post-market surveillance study aims to evaluate the safety and effectiveness of the Angio-SealTM VIP VCD in patients undergoing endovascular procedures via femoral access in real-world setting.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Post-Market Clinical Investigation of the FemoSeal™ VCS: A Prospective, Multi-Center Observational European Study

NCT05027698

Vascular Closure Endovascular Procedure Hemostasis +1 more

COMPLETED

Post-Market Study of the St. Jude Medical Angio-Seal™ V-Twist Integrated Platform (VIP) Vascular Closure Device

NCT01858636

Vascular Closure

COMPLETED

X-Seal EU Post-Market Clinical Follow-Up Protocol

NCT02406612

Femoral Arteriotomy Closure

COMPLETED NA

Comparison of the FemoSeal® Arterial Closure Device to Manual Compression After Coronary Angiography

NCT01001663

Coronary Angiography Via Femoral Artery Access

COMPLETED PHASE4

Clinical Investigation for Safety and Efficacy Study of CELT ACD (Arterial ClosureDevice)

NCT01600482

Cardiac Disease Coronary Artery Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The proposed Post-Market Clinical Follow-up study is a prospective, multi-Center, observational study, aiming to further demonstrate the safety and effectiveness of the Angio-SealTM VIP VCD in achieving hemostasis of femoral artery access site in real-world subjects undergoing percutaneous endovascular procedures. 230 patients will be enrolled at up to 6 sites in Europe. Follow-ups are scheduled at 30 days (+7 days) by hospital visit or telephone call.

The sponsor shall provide training and the necessary guidelines to assist each investigation site on the data collection in the eCRF. Each site is responsible to report the available data requested by the CIP. In order to ensure data quality, validation \& consistency, edit checks will be designed during database development. Data Management team and the study monitors will be responsible to review the data and raise queries in the eCRF. Data cleaning will be done in regular intervals specified in DMP. The final clean standardised datasets will be available prior to database lock for data analysis. An audit trail logging all data entered and edited is available within the EDC system. All source documents are maintained in the hospital files ready for inspection by the Sponsor and regulatory authorities upon request. The Sponsor will inform the investigator of the time period for retaining these records as per applicable regulatory requirements.

The study will be monitored at all stages of its development by study monitors appointed by the sponsor. Study monitors are designated as Sponsor representatives and are assigned to oversee the conduct and progress of the study at each site in accordance with the Monitoring Plan established for this clinical investigation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vascular Closure Endovascular Procedure Hemostasis Peripheral Vascular Disease Femoral Artery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Closure of the femoral arterial puncture site

Patient will undergo a diagnostic or interventional endovascular procedure, compatible with the use of Angio-Seal™ VIP VCD.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject is ≥ 18 years old
2. Subject is willing and able to complete the follow-up requirements
3. Subject has the mental capacity (i.e., does not require the use of a Legally Authorized Representative) to sign the study Informed Consent Form (ICF)
4. Patient undergoing diagnostic or interventional endovascular procedure compatible with the use of Angio-SealTM VIP VCD
5. Puncture site located at the femoral artery (i.e., between the inguinal ligament and the bifurcation of the superficial femoral and profunda femoris arteries)
6. Angio-SealTM VIP VCD deployed as per instruction for use by a trained operator

Exclusion Criteria

* Use of the Angio-SealTM VIP VCD on puncture sites other than the femoral artery

1. Repuncture of the femoral artery within 90 days at the same access site
2. Lumen diameter of femoral artery \< 4 mm
3. Patients with clinically significant peripheral vascular disease at the puncture site (luminal narrowing of \>40% within 5 mm of the puncture site)
4. Puncture site at or distal to the bifurcation of the superficial femoral and profunda femoris artery
5. Puncture site proximal to the inguinal ligament
6. Procedure sheath placed through the superficial femoral artery into the profunda femoris
7. Multiple femoral punctures
8. Known or suspected posterior femoral wall puncture
9. Use of \> 8F primary introducer sheaths or devices for an 8Fr Angio-SealTM VIP, or use of a \>6Fr primary introducer sheaths or devices for a 6Fr Angio-SealTM VIP
10. Any condition that would make use of Angio-SealTM VIP VCD inappropriate (as per IFU and investigators' discretion)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No